trial · primary record
Daratumumab (Intravenously)
Newly Diagnosed Multiple Myeloma (NDMM)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 52 |
| Primary completion | 2029-05-05 |
| Primary endpoint | Post-induction MRD negativity rate |
| Registry ID | NCT07891923 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:31.639Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07891923
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.